DIRAS1 Inhibitors

Chemicals designated as DIRAS1 inhibitors can primarily be grouped into several classes, each targeting different aspects of DIRAS1 functionality or its role in associated signaling pathways. One such class is the farnesyltransferase inhibitors, represented by Manumycin A and Lonafarnib. These compounds can inhibit the post-translational modification of DIRAS1, thereby affecting its localization and subsequent interaction with downstream targets.

A second major class focuses on kinase inhibitors that affect downstream effectors and related pathways. For instance, PI3K inhibitors like LY294002 and Wortmannin can disrupt the cell survival pathway, interfering with DIRAS1 functionality. ERK and MEK inhibitors like PD98059 and U0126 target MAPK pathways, which can be relevant to DIRAS1's involvement in cell survival and apoptosis. In this context, other inhibitors like SP600125 can target JNK and NF-κB pathways, respectively. In summary, the compounds listed can affect DIRAS1 function either through direct inhibition or via interference in relevant cellular pathways, offering different routes for scientific investigation into DIRAS1 modulation.